Skip to main content

ImmunoGen, Inc.

IMGNDelisted Feb 12, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0000855654

ImmunoGen, Inc. was delisted on Feb 12, 2024; its insiders filed their last Form 4 on Feb 12, 2024; 327 institutions reported holding it in 13F filings for Q4 2023, worth $7.54B in total; Maverick Capital was the only superinvestor holding it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
327
Q4 2023, +52 vs. previous quarter
13F value
$7.54B
Reported value at the end of Q4 2023
Superinvestors holding
1
At the end of Q4 2023

From SEC filings, in USD.

Revenue, FY2022
$108.8M
+55.7% year over year
Net income, FY2022
-$222.9M
No comparable prior period
Free cash flow, FY2022
-$231.2M
No comparable prior period
Revenue, Q3 FY2023
$113.4M
+637.7% year over year

Revenue flow, FY2022

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2022: $222.9M (204.9% of revenue).

Superinvestors holding IMGN, Q4 2023

Go to the superinvestors tab

1 superinvestor reports holding ImmunoGen, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Maverick Capital

Lee Ainslie

1.5%

ImmunoGen, Inc.'s share of the portfolio

Shares
2,493,217
Value
$73.9M

Latest insider trades

See all insider trades

Open-market purchases and sales by ImmunoGen, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 6, 2024 (view filing)Feb 51 dayCoen Stacy AnnSVP & CHIEF BUSINESS OFFICERSSale−4.58K$29.30−$134.3K−5.9%73.3K after10b5-1
Feb 6, 2024 (view filing)Feb 51 dayWingrove TheresaSVP OF REGULATORY AFFAIRSSSale−12.0K$29.30−$352.4K−36.4%21.0K after10b5-1
Feb 6, 2024 (view filing)Feb 51 dayEnyedy Mark JCHIEF EXECUTIVE OFFICERSSale−20.1K$29.28−$588.7K−3.3%584.4K after10b5-1
Feb 6, 2024 (view filing)Feb 51 dayLentini ReneeVP & PRIN ACCTG OFFICERSSale−2.63K$29.30−$77.1K−15.2%14.7K after10b5-1
Jan 18, 2024 (view filing)Jan 162 daysWingrove TheresaSVP OF REGULATORY AFFAIRSSSale−187.7K$29.64−$5.56M−98.2%3.43K after10b5-1
Dec 27, 2023 (view filing)Dec 261 dayLentini ReneeVP & PRIN ACCTG OFFICERSSale−6.55K$29.74−$194.7K−43.7%8.45K after10b5-1
Dec 19, 2023 (view filing)Dec 154 daysWingrove TheresaSVP OF REGULATORY AFFAIRSSSale−117.4K$29.40−$3.45M−97.7%2.81K after10b5-1
Dec 5, 2023 (view filing)Nov 305 daysLateCoen Stacy AnnSVP & CHIEF BUSINESS OFFICERSSale−3.83K$29.20−$111.7K−10.4%33.1K after10b5-1
Dec 5, 2023 (view filing)Nov 305 daysLatePeterson KristineDirectorSSale−20.0K$28.90−$578.0K−100.0%0 after10b5-1
Dec 1, 2023 (view filing)Nov 29-302 daysWingrove TheresaSVP OF REGULATORY AFFAIRSSSale−171.2K$28.46−$4.87M−98.4%2.81K after2 lots10b5-1

Top 10 13F holders, Q4 2023

See all 327 holders

The largest institutional positions in ImmunoGen, Inc. at the end of Q4 2023; share changes are against Q3 2023.

Institutions holding IMGN in Q4 2023
InstitutionSharesValue% of portfolioChange in sharesAction
Vanguard Group Inc25,466,950$755.1M0.02%+984,795+4.0%Added
Ra Capital Management, L.P.23,750,601$704.2M11.00%+10,428,313+78.3%Added
BlackRock Inc.21,824,392$647.1M0.02%+1,550,533+7.6%Added
Redmile Group, LLC16,423,922$487.0M17.42%−1,079,495−6.2%Reduced
Janus Henderson Group PLC11,043,986$327.5M0.20%−6,640,830−37.6%Reduced
State Street Corp8,075,671$239.4M0.01%−1,476,181−15.5%Reduced
Fairmount Funds Management LLC5,929,592$175.8M18.58%00.0%Unchanged
Pentwater Capital Management LP5,662,500$167.9M3.15%+5,662,500New
Norges Bank5,539,334$164.2M0.03%+3,484,245+169.5%Added
Geode Capital Management, LLC5,382,875$159.6M0.02%+482,900+9.9%Added